ARCA biopharma to Present at Biotech Showcase 2017
January 04 2017 - 8:30AM
Business Wire
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
applying a precision medicine approach to developing
genetically-targeted therapies for cardiovascular diseases, today
announced that it will present a corporate overview at the Biotech
Showcase 2017, taking place January 9-11, 2017 in San Francisco,
California.
Date:
Monday, January 9, 2017
Time:
2:00 p.m. (Pacific Time)
Presenter:
Thomas Keuer, Chief Operating Officer
Webcast/Presentation: The live webcast will be available
at https://event.webcasts.com/starthere.jsp?ei=1130353 and
http://arcabio.com/investors/investor-presentations/. ARCA’s
corporate investor presentation will be posted in the Investor
Relations section of its website (www.arcabio.com).
Replay Information: A replay of the webcast is expected
to be available approximately two hours after the presentation on
January 9, 2017, and will remain available for 90 days. The replay
can be accessed at
https://event.webcasts.com/starthere.jsp?ei=1130353.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted
therapies for cardiovascular diseases through a precision medicine
approach to drug development. The Company's lead product candidate,
GencaroTM (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for atrial fibrillation. ARCA has identified common
genetic variations that it believes predict individual patient
response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA
has a collaboration with Medtronic, Inc. for support of the
GENETIC-AF trial. For more information, please visit
www.arcabio.com.
Safe Harbor Statement
This press release and the anticipated presentation contain
"forward-looking statements" for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements
regarding, potential timing for patient enrollment in the
GENETIC-AF trial, potential timeline for GENETIC-AF trial
activities, the potential outcome of the GENETIC-AF Phase 2B
interim analysis, the sufficiency of the Company’s capital to
support its operations, the potential for genetic variations to
predict individual patient response to Gencaro, Gencaro’s potential
to treat atrial fibrillation, future treatment options for patients
with atrial fibrillation, and the potential for Gencaro to be the
first genetically-targeted atrial fibrillation prevention
treatment. Such statements are based on management's current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with:
the Company's financial resources and whether they will be
sufficient to meet the Company's business objectives and
operational requirements; results of earlier clinical trials may
not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process;
and, the impact of competitive products and technological changes.
These and other factors are identified and described in more detail
in ARCA’s filings with the SEC, including without limitation the
Company’s annual report on Form 10-K for the year ended December
31, 2015, and subsequent filings. The Company disclaims any intent
or obligation to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170104005812/en/
ARCA biopharma, Inc.Derek Cole,
720-940-2163derek.cole@arcabio.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Sep 2023 to Sep 2024